Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels

The use of immune checkpoint inhibitors (ICI) for non-small-cell lung cancer (NSCLC) is increasing. Currently validated indications include advanced and locally advanced disease [1]. Classically, r...